MT2A

Across TCGA pan-cancer cohorts, MT2A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MT2A data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MT2A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MT2A expression acts as an unfavorable survival marker.

CCRCC, LSCC, and PDAC are the cancer types where MT2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.460	0.849	.008	26	view →
LSCC	DFS	Tertile	II,III,IV	0.518	0.848	.017	15	view →
PDAC	DFS	Tertile	All	0.326	0.495	.024	10	view →
LUAD	OS	Quartile	All	0.916	1.000	.030	3	view →
UCEC	DFS	Median	All	0.935	1.000	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MT2A–CCRCC (OS)

Open the CCRCC breakdown →